Biogen appoints Christopher Viehbacher as President and CEO effective Nov 14, 2022

BIOGEN INC.

Viehbacher succeeds Michel Vounatsos, who steps down as CEO and from the Board.
Viehbacher receives $1.6M base salary, 150% target bonus, and initial equity awards totaling $28M (options + PSUs).
He must purchase at least $2M of Biogen stock; then receive an RSU grant of $2M vesting in 3 years.
Severance: 1.5x salary plus target bonus if terminated without cause or for good reason; 2x if change in control.
Viehbacher co-founded Gurnet Point Capital, former global CEO of Sanofi.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michel Vounatsos

CEO

BIIB · BIOGEN INC.

Successor: Christopher A. Viehbacher
Filed: November 10, 2022, 6:59 PM ET

Michel Vounatsos will step down as Biogen’s CEO and will resign from the Board.

Appointed

Christopher A. Viehbacher

President and CEO

BIIB · BIOGEN INC.

Effective: 2022-11-14
Filed: November 10, 2022, 6:59 PM ET

appointed Christopher A. Viehbacher, age 62, to serve as President and CEO of Biogen, beginning November 14, 2022.

Appointed

Christopher A. Viehbacher

Director

BIIB · BIOGEN INC.

Effective: 2022-11-14
Filed: November 10, 2022, 6:59 PM ET

Mr. Viehbacher will succeed Michel Vounatsos as director of Biogen effective November 14, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michel Vounatsos departed as CEO at BIOGEN INC..

Action: stepped down
Role: CEO

Exact text from the filing

Michel Vounatsos will step down as Biogen’s CEO and will resign from the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher A. Viehbacher was appointed as President and CEO at BIOGEN INC..

Action: appointed
Role: President and CEO

Exact text from the filing

appointed Christopher A. Viehbacher, age 62, to serve as President and CEO of Biogen, beginning November 14, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher A. Viehbacher was appointed as Director at BIOGEN INC..

Action: appointed
Role: Director

Exact text from the filing

Mr. Viehbacher will succeed Michel Vounatsos as director of Biogen effective November 14, 2022

View on SEC.gov

BIOGEN INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-281950

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.